- Dr. Kantor joins founding management team to direct ITI's Center for
Critical Path Immunology -
SAN FRANCISCO, April 7, 2008 /PRNewswire/ -- The Immune Tolerance Institute Inc., (ITI) today announced that Aaron B. Kantor, Ph.D. has joined the company in the position of Chief Scientific Officer, reporting to Louis A. Matis, M.D., President and Chief Executive Officer. Prior to joining ITI, Dr. Kantor served as Executive Director of Cell and Molecular Biology for Biomarker Discovery Sciences at Pharmaceutical Product Development, Inc. (PPD), a leading global contract research organization (CRO) providing discovery, development and post-approval services and compound partnering programs for pharmaceutical, biotechnology, medical device, academic and government organizations.
"We are very pleased to have Aaron join the founding management team at ITI, as he brings to the company broad-based expertise in applying a range of bioanalytical technologies to the discovery of biological markers for human diseases," said Dr. Matis. "His extensive record of accomplishments in both academic and industry settings will be invaluable to ITI as we build our Center for Critical Path Immunology and leverage the partnering opportunities for our integrated diagnostic platforms."
Dr. Kantor, 49, has more than 20 years of research and development
experience. He joined PPD in 2005 when the company acquired the biomarker
business of SurroMed, Inc., where he was a founding scientist and director
of cell and molecular biology. At PPD, his work centered on the broad
effort to discover biological markers for human diseases using
bioanalytical methods including cytometry, immunoassays, proteomics,
metabolomics and bioinformatics tools. He supervised an interdisciplinary
group of scientists and engineers in this effort and led the development
and implementation of a laser scanning cytometry platform for clinical
studies. His responsibilities
|SOURCE The Immune Tolerance Institute Inc.|
Copyright©2008 PR Newswire.
All rights reserved